GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - APREA THERAPEUTICS INC

Financial Performance:

• The transcript does not disclose specific revenue figures, earnings, profit margins, debt levels, or cash flow statements, as the company is in the clinical development stage without commercial products.
• Current cash runway is projected to extend through Q1 2028.
• Recent financing activities occurred at the end of March to fund the continued development of the lead asset.
• Capital allocation is heavily directed toward the APR 1051 program through the first half of 2027.

Guidance and Future Outlook:

• Primary milestone target is the completion of the APR 1051 dose escalation study by the first half of 2027.
• Upcoming data updates are expected at the Triple Meeting in Barcelona, focusing on expanded safety profiles, higher dose PK data, and PD biomarkers (target engagement via skin biopsy).
• Management anticipates shifting from broad Phase 1 dose escalation to a more focused dose expansion phase based on biomarker identification.
• Accelerated approval pathway via the FDA is a long-term goal, contingent upon successful Phase 2 data.
• Plans to finalize a companion diagnostic agreement with a leading pharmaceutical partner to enable registration.

Business Segments and Product Lines:

• Lead Asset (APR 1051): A selective WEE1 inhibitor designed to avoid PLK1/2/3 inhibition, addressing toxicity liabilities of earlier generation inhibitors; currently in Phase 1 with a demonstrated 17-hour half-life and improved tolerability.
• Pipeline Expansion:
  • Ovarian Cancer & USC: Enrollment planned for 50 patients in platinum-resistant ovarian cancer (Cyclin E overexpressing) and uterine serous carcinoma (USC).
  • Combination Therapies: Investigating synergy with platinum chemotherapy in resistant head and neck and colorectal cancers, and potential combinations with radiation, IO, or ADCs.
• ATR Inhibitor (ATRN119): Dose escalation complete; program shifted to combination strategies (with radiation/chemo) due to less satisfying monotherapy activity; seeking academic collaborations.
• Preclinical Assets: Novel DERC1 target in lead optimization; P53 program being re-evaluated following previous Phase 3 discontinuation.

Market and Competitive Landscape:

• Competitive landscape includes competitors like Zentalis, Merck, and AstraZeneca, who have also targeted WEE1 inhibition.
• Aprea differentiates via high selectivity for WEE1 over PLK families and optimized pharmacokinetics (long half-life, low Cmax) to widen the therapeutic window.
• Market opportunity is considered large, drawing parallels to PARP inhibitors (e.g., Olaparib, >$3B annual sales), with potential for combination regimens across tumor types.
• Management is awaiting competitive data from Zentalis, expected in Q1 or H1 of the following year.

Risks and Challenges:

• Clinical Success: Success depends on identifying the correct biomarkers and patient subpopulations that respond; current data is limited to small cohorts.
• Toxicity Management: Potential on-target neutropenia remains a risk, though management believes the therapeutic window is improved; specific toxicity thresholds (e.g., DLTs) are still being defined.
• Biomarker Dependency: The strategy relies heavily on developing and validating predictive biomarkers (IHC, genetic alterations) which may delay expansion.
• Development Timelines: Uncertainty exists regarding the timeline for definitive response rates and durability data.

Management Commentary and Tone:

• Tone: Optimistic yet cautious; management emphasizes the necessity of "data-driven" decisions for patient selection and dose expansion.
• Confidence: Strong belief in the differentiation of APR 1051 (selectivity and PK profile) compared to class liabilities.
• Strategic Focus: Prioritizing a "mid-phase 2" build within the ongoing Phase 1 trial to identify responsive populations before broader expansion.

Analyst Questions and Answers:

• Differentiation: Confirmed APR 1051 avoids co-inhibition of PLK1, 2, and 3, preventing the need for higher dosing that causes toxicity in previous generation drugs.
• Dose Selection: No fixed doses announced yet; FDA's "Project Optimist" guidelines will drive the selection of two expansion doses, expected to be known in the next 1-2 quarters.
• Patient Selection: Enrollment focuses on specific alterations (FBXW7, KRAS, PPP2R1A, Cyclin E overexpression); IHC assays are being finalized for USC and Cyclin E overexpressing patients.
• Enrollment Metrics: Tracking approximately one patient per site per month; currently 8 patients in screening with sites expanding from 3 to 9.
• Market Potential: WEE1 mechanism allows for monotherapy and combination use with chemo, IO, and ADCs, suggesting a large addressable market.

Other Key Points:

• Clinical sites are accelerating enrollment with a focus on expanding the footprint to 9 active sites.
• The P53 legacy asset is being revisited internally to identify patients who previously derived benefit, driven by continued patient interest.
• ATR program is pivoting exclusively to collaboration models for combination therapies rather than internal development of monotherapy.
• Biomarker strategy remains central to the company's "synthetic lethality" approach, aiming to match specific genetic mutations with the drug for precise patient eligibility.